3 results
Approved WMOCompleted
Part 1: The primary objective is to investigate if the RNFL-ac in PD patients differs significantly from the RNFL-ac in healthy controls.Secondary Objectives are:1) to investigate if the RNFL-ac can be used to differentiate PD patients from healthy…
Approved WMOCompleted
To evaluate the dose response relationship of LNP023 on the reduction in proteinuria versus placebo after 90 days of treatment in patients with IgA nephropathy.
Approved WMOCompleted
The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.